25.National Institute for Health and Clinical Excellence. Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes London: NICE, 2009.26.Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med2007;357:1716-30.28.Diabetes UK. Recommendations for the management of diabetes in primary care

1.United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
2.National Institute for Health and Clinical Excellence. Type 2 Diabetes. National clinical guideline for management in primary and secondary care (update) London: NICE, 2008.
3.Williams B, Poulter NR, Brown MJ, Davis M, et al

Литература
1. Diabetes UK. Recommendations for the management of diabetes in primary care. London: Diabetes UK, 2000.
2. The Information Centre, Information and Statistical Governance, Department of Health 2008

46. Feagan BG, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH et al. A comparison of 
methotrexate with placebo for the maintenance of remission in Crohn's disease. North American 
Crohn's Study Group Investigators. N Engl J Med 2000;342(22):1627-32.
47

24. Mackalski BA, Bernstein CN. New diagnostic imaging tools for inflammatory bowel disease. Gut 2006;55(5):733-41.
25. Nayar M, Rhodes JM

Литература
1. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55(6):749-53.
2. Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J